Our former SAB member Dr. Paul Edison is running an investigator initiated phase 2b trial of liraglutide in mild Alzheimer's.
"This study aims to investigate the effect of liraglutide on glucose metabolism, MRI volume changes, amyloid load, tau formation and neuroinflammation using PET and MRI scans."